A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. [electronic resource]
Producer: 20150917Description: 146-59 p. digitalISSN:- 1097-4172
- Adenocarcinoma -- drug therapy
- Adenocarcinoma of Lung
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Cell Cycle Checkpoints
- Checkpoint Kinase 1
- DNA Damage
- Disease Models, Animal
- Drug Synergism
- Enzyme Inhibitors -- pharmacology
- Heterografts
- Humans
- Intracellular Signaling Peptides and Proteins -- antagonists & inhibitors
- Lung Neoplasms -- drug therapy
- Mice
- Neoplasm Transplantation
- Protein Kinases -- metabolism
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins -- metabolism
- Proto-Oncogene Proteins B-raf -- metabolism
- Proto-Oncogene Proteins p21(ras)
- Tumor Cells, Cultured
- ras Proteins -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.